Central GLP-1Rs distributed across the brain are predicted to mediate the anorectic and illness-like effects that accompany the therapeutic benefits of GLP-1–based analogs used for the treatment of diabetes and obesity. This evidence concerns the gene GCG and diabetes mellitus.